Impact of COVID-19 in patients with autoimmune bullous diseases: Report from an international registry.

Authors	MEIJER Joost M RASHID Hanan VERGADI Styliani ANTIGA Emiliano VEZZOLI Pamela BALESTRI Riccardo PATSATSI Aikaterini UZUN Soner SKILJEVIC Dusan JEDLIČKOVÁ Hana VOJTĚCHOVÁ Lucia CORRA Alberto PONZIANI Alessandra GÜNTHER Claudia CIANCHINI Giuseppe SCHEFZYK Matthias MARZANO Angelo GIOVANNI Di Zenzo SHIMANOVICH Iakov FAIRLEY Janet MASCARÓ Jose M CAPRONI Marzia MAGLIE Roberto SCHMIDT Enno HORVÁTH Barbara
Year of publication	2023
Type	Article in Periodical
Magazine / Source	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://onlinelibrary.wiley.com/doi/10.1111/jdv.19242
Doi	http://dx.doi.org/10.1111/jdv.19242
Keywords	COVID-19; autoimmune bullous diseases
Description	For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ?10?mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.